Valuation: Gilead Sciences, Inc.

Market Cap 161B 141B 131B 121B 228B 15,373B 232B 1,555B 610B 7,529B 605B 592B 26,099B P/E 2026 *
-46.8x
P/E 2027 * 16.7x
Enterprise Value 171B 150B 138B 128B 242B 16,275B 246B 1,647B 646B 7,971B 641B 627B 27,631B EV / Sales 2026 *
5.6x
EV / Sales 2027 * 4.98x
Free-Float
99.88%
Yield 2026 *
2.5%
Yield 2027 * 2.59%
1 day-3.72%
1 week-1.10%
Current month+2.76%
1 month+3.15%
3 months-6.59%
6 months+7.21%
Current year+5.78%
1 week 127.88
Extreme 127.88
137.7
1 month 122.43
Extreme 122.43
137.7
Current year 116.88
Extreme 116.88
157.29
1 year 107.75
Extreme 107.75
157.29
3 years 62.07
Extreme 62.07
157.29
5 years 57.16
Extreme 57.165
157.29
10 years 56.56
Extreme 56.56
157.29
Manager TitleAgeSince
Chief Executive Officer 61 2019-02-28
Director of Finance/CFO 56 2019-10-31
Compliance Officer - 2025-12-17
Director TitleAgeSince
Director/Board Member 58 2016-08-18
Director/Board Member 73 2017-12-31
Director/Board Member 72 2018-05-08
Date Insider Type Main position Quantity % Market Cap.
Jun. 30Sell

Chief Executive Officer

-15,000 0.0012%
Jun. 14Sell

Executive/Senior Manager

-3,000 0.0002%
Jun. 14Sell

Chief Financial Officer

-3,000 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-3.72%-1.10%+18.41%+70.56% 161B
-2.33%-2.09%+49.88%+170.51% 1,060B
-0.82%-2.30%+63.79%+62.00% 619B
-0.73%-4.98%+28.91%+82.99% 438B
+0.33%-1.17%+31.07%+27.09% 333B
-0.02%-2.85%+29.15%+45.24% 282B
-3.89%-11.22%+22.81%+27.30% 267B
+0.66%-1.42%-26.59%-37.71% 218B
-0.06%-2.88%+23.07%+62.33% 196B
-0.33%-0.62%-5.77%-32.90% 138B
Average -1.09%-2.98%+23.47%+47.74% 371.17B
Weighted average by Cap. -1.28%-2.87%+35.17%+79.57%

Financials

2026 *2027 *
Net sales 30.47B 26.74B 24.67B 22.78B 43.16B 2,905B 43.92B 294B 115B 1,423B 114B 112B 4,933B 32.37B 28.41B 26.21B 24.2B 45.86B 3,087B 46.66B 312B 123B 1,512B 122B 119B 5,240B
Net income -3.37B -2.96B -2.73B -2.52B -4.78B -322B -4.86B -32.55B -12.77B -158B -12.66B -12.39B -546B 9.55B 8.38B 7.73B 7.14B 13.53B 911B 13.76B 92.14B 36.14B 446B 35.85B 35.07B 1,546B
Net Debt 9.46B 8.3B 7.66B 7.07B 13.4B 902B 13.64B 91.29B 35.81B 442B 35.52B 34.74B 1,532B -96.43M -84.64M -78.1M -72.09M -137M -9.2B -139M -931M -365M -4.5B -362M -354M -15.61B
Logo Gilead Sciences, Inc.
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.2%): for the treatment of HIV (71.8% of net sales), oncology diseases (11.2%), hepatitis B virus (11.1%), Ebola virus (3.2%) and other (2.7%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.8%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (70.9%), Europe (17.2%) and other (11.9%).
Employees
17,000
Date Price Change Volume
26-07-10 $129.83 -3.72% 5,935,997
26-07-09 $134.84 -0.72% 5,839,339
26-07-08 $135.82 -0.40% 8,454,142
26-07-07 $136.36 +5.21% 9,177,296
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
129.83USD
Average target price
158.30USD
Spread / Average Target
+21.93%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GILD Stock